Phase 1 Ovarian Cancer Trial, Recruiting

Written by an AI model from ClinicalTrials.gov eligibility criteria and checked on a sample basis. Please confirm against the original criteria.

Who might be able to join this trial:

• People aged 18 or older at the time of joining the study.
• People who are willing and able to follow the study schedule, including attending appointments and completing follow-up visits, for the full duration of the trial.
• People who have been diagnosed (confirmed by laboratory tissue testing) with ovarian cancer, fallopian tube cancer, or peritoneal carcinoma (cancer affecting the lining of the abdomen).
• People whose cancer has stopped responding to platinum-based chemotherapy, either during treatment or within 6 months after finishing it.
• People who have previously received anti-blood-vessel-targeting therapies (such as bevacizumab) are still eligible to be considered.
• People who have received any number of prior cancer treatments before this trial.
• People who are generally well enough to carry out light activity and care for themselves (based on a standard fitness scale used by doctors, rated 0 or 1 out of 5).
• People whose blood counts, liver function, and kidney function meet the minimum levels set by the trial (confirmed through blood tests).
• People who either have confirmed post-menopausal status or have a negative pregnancy test before starting treatment. People of childbearing potential must agree to use two forms of contraception during the study and for three months after the last dose.
• People whose cancer can be measured on scans using standard criteria (known as RECIST v1.1).

Who may not be able to join:

• People who have received radiation, chemotherapy, immunotherapy, or any other cancer treatment within 2 weeks before the study start date.
• People who have used an anti-cancer or experimental drug within 28 days (or 5 half-lives of that drug, whichever is shorter) before the study start date, with at least 10 days required between stopping prior treatment and starting the study.
• People with known or suspected bowel conditions that could increase the risk of digestive side effects, such as inflammatory bowel disease, bowel obstruction, a history of bowel obstruction, or cancer directly affecting the bowel.
• People who are currently pregnant or breastfeeding.
• People who have had major surgery within 28 days before the study start date.
• People with unstable heart function, including certain abnormal heart rhythms requiring treatment, significant heart failure, or a heart attack within the past 3 months.
• People with an active, uncontrolled infection currently requiring intravenous antibiotics, antivirals, or antifungal medicines within one week before the first dose (people with controlled infections or taking preventive antibiotics may still be considered).
• People with a known history of hepatitis A, B, or C, active hepatitis B or C infection detected by blood tests, or a positive HIV test.
• People with significant nerve damage in their hands or feet rated above a moderate level (Grade 2) at the time of screening.
• People with serious psychiatric or medical conditions that could interfere with completing treatment.
• People who have participated in another experimental cancer treatment study within 3 weeks before the study start date.
• People currently receiving any other approved or experimental cancer treatment (steroids are an exception).
• People with active bleeding problems or blood clotting issues, including peptic ulcer bleeding, nosebleeds, or spontaneous bleeding within 4 weeks before the study start date.
• People with brain tumour deposits that are causing symptoms.
• People with significant problems with blood clotting that are not related to a prescribed blood-thinning medication.
• People who have coughed up notable amounts of blood within 1 month before joining the study.
• People with wounds, ulcers, or bone fractures that are not healing.
• People with a known allergic reaction to any of the study drugs: lurbinectedin, paclitaxel, or bevacizumab, or to any of their ingredients.

Important: Always verify eligibility with the trial site directly before applying.